Allison Jordan, DO
Neurology · Columbus, OHNPI 1073932406
Payments from drug & device makers
What this record shows
This record is dominated by grants: $90,000 of the $98,353 with a category attached, or 91.5%. Biogen accounts for 91.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $90,000 and has fallen 97.1% since, to $2,593 in 2025. Among neurology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $7565.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$90K
- Amgen$6K
- TG Therapeutics, Inc.$3K
- AstraZeneca$106
- Sanofi$14
Across 14 payments — averaging $36,335 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$506K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$2,2602%
- Speaking & faculty fees$4,9505%
- Grants$90,00092%
- Travel & lodging$8611%
- Food & beverage$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 1 | $90,000 |
| Amgen | 8 | $5,640 |
| TG Therapeutics, Inc. | 2 | $2,593 |
| AstraZeneca | 1 | $106 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$98,353 in reported general payments places this provider in the 90th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 27 | $257,459 |
| Dalfampridine ErDalfampridine | 33 | $34,947 |
| MyrbetriqMirabegron | 16 | $6,181 |
| Gabapentin | 34 | $634 |
| Baclofen | 42 | $607 |
| Pregabalin | 20 | $557 |
| Tizanidine Hcl | 25 | $407 |
| Levetiracetam | 14 | $257 |
| Sumatriptan Succinate | 13 | $122 |
| Cyclobenzaprine Hcl | 11 | $121 |
| Trazodone Hcl | 16 | $24 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Douglas ScharreColumbus$191K
- Aristide MerolaColumbus$133K
- Miriam FreimerColumbus$105K
- Aram ZabetiCincinnati$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.